$OCGN
Ocugen, Inc.

2020 Q2 Form 10-Q Financial Statement

#000162828020012662 Filed on August 14, 2020

View on sec.gov

Income Statement

Concept 2020 Q2 2019 Q2
Revenue $43.00K $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $1.780M -$790.0K
YoY Change -325.32% -127.92%
% of Gross Profit
Research & Development $1.630M $446.0K
YoY Change 265.47% -90.0%
% of Gross Profit
Depreciation & Amortization $20.00K $110.0K
YoY Change -81.82% -45.0%
% of Gross Profit
Operating Expenses $3.409M $2.329M
YoY Change 46.4% -68.03%
Operating Profit -$3.366M -$2.329M
YoY Change 44.56% -68.03%
Interest Expense $248.0K $261.6K
YoY Change -5.19% 717.38%
% of Operating Profit
Other Income/Expense, Net -$248.0K -$1.210M
YoY Change -79.51% -134.51%
Pretax Income -$3.610M -$440.0K
YoY Change 720.45% -88.36%
Income Tax
% Of Pretax Income
Net Earnings -$3.614M -$3.539M
YoY Change 2.12% -6.31%
Net Earnings / Revenue -8404.65%
Basic Earnings Per Share -$0.19
Diluted Earnings Per Share -$0.19 -$40.07K
COMMON SHARES
Basic Shares Outstanding 83.54M shares 94.60M shares
Diluted Shares Outstanding 83.54M shares

Balance Sheet

Concept 2020 Q2 2019 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $14.97M $2.790M
YoY Change 436.56% -68.19%
Cash & Equivalents $14.97M $678.5K
Short-Term Investments
Other Short-Term Assets $7.920M $410.0K
YoY Change 1831.71% -53.41%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $22.89M $3.200M
YoY Change 615.4% -66.85%
LONG-TERM ASSETS
Property, Plant & Equipment $232.4K
YoY Change
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $482.7K
YoY Change
Total Long-Term Assets $866.2K $0.00
YoY Change -100.0%
TOTAL ASSETS
Total Short-Term Assets $22.89M $3.200M
Total Long-Term Assets $866.2K $0.00
Total Assets $23.76M $3.200M
YoY Change 642.47% -78.88%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $507.9K $538.0K
YoY Change -5.6% -75.62%
Accrued Expenses $2.085M $253.0K
YoY Change 724.08% -84.87%
Deferred Revenue
YoY Change
Short-Term Debt $4.068M $0.00
YoY Change
Long-Term Debt Due $4.070M
YoY Change
Total Short-Term Liabilities $7.041M $791.0K
YoY Change 790.18% -93.21%
LONG-TERM LIABILITIES
Long-Term Debt $2.019M $0.00
YoY Change
Other Long-Term Liabilities $0.00 $11.14M
YoY Change -100.0% -58.63%
Total Long-Term Liabilities $2.095M $11.14M
YoY Change -81.2% -58.63%
TOTAL LIABILITIES
Total Short-Term Liabilities $7.041M $791.0K
Total Long-Term Liabilities $2.095M $11.14M
Total Liabilities $9.136M $11.93M
YoY Change -23.43% -69.08%
SHAREHOLDERS EQUITY
Retained Earnings -$59.00M -$229.5M
YoY Change -74.29% 1.18%
Common Stock $1.351M $220.8M
YoY Change -99.39% 8.55%
Preferred Stock
YoY Change
Treasury Stock (at cost) $47.86K
YoY Change
Treasury Stock Shares
Shareholders Equity $14.62M -$6.106M
YoY Change
Total Liabilities & Shareholders Equity $23.76M $3.200M
YoY Change 642.47% -78.88%

Cashflow Statement

Concept 2020 Q2 2019 Q2
OPERATING ACTIVITIES
Net Income -$3.614M -$3.539M
YoY Change 2.12% -6.31%
Depreciation, Depletion And Amortization $20.00K $110.0K
YoY Change -81.82% -45.0%
Cash From Operating Activities -$3.080M -$3.060M
YoY Change 0.65% -41.38%
INVESTING ACTIVITIES
Capital Expenditures $20.00K $0.00
YoY Change -100.0%
Acquisitions
YoY Change
Other Investing Activities $0.00 $110.0K
YoY Change -100.0%
Cash From Investing Activities $20.00K $110.0K
YoY Change -81.82% -107.48%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 14.84M -1.780M
YoY Change -933.71% 3460.0%
NET CHANGE
Cash From Operating Activities -3.080M -3.060M
Cash From Investing Activities 20.00K 110.0K
Cash From Financing Activities 14.84M -1.780M
Net Change In Cash 11.78M -4.730M
YoY Change -349.05% -29.82%
FREE CASH FLOW
Cash From Operating Activities -$3.080M -$3.060M
Capital Expenditures $20.00K $0.00
Free Cash Flow -$3.100M -$3.060M
YoY Change 1.31% -18.4%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001372299
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Amendment Flag
AmendmentFlag
false
CY2020Q2 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilities
dei Entity Address Address Line2
EntityAddressAddressLine2
Suite 160
dei Entity Address City Or Town
EntityAddressCityOrTown
Malvern
dei Entity Address State Or Province
EntityAddressStateOrProvince
PA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
19355
CY2019Q4 us-gaap Finance Lease Liability Statement Of Financial Position Extensible List
FinanceLeaseLiabilityStatementOfFinancialPositionExtensibleList
us-gaap:OtherLiabilities
dei City Area Code
CityAreaCode
484
dei Local Phone Number
LocalPhoneNumber
328-4701
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2020-06-30
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-36751
dei Entity Registrant Name
EntityRegistrantName
OCUGEN, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
04-3522315
dei Entity Address Address Line1
EntityAddressAddressLine1
5 Great Valley Parkway
dei Security12b Title
Security12bTitle
Common Stock, par value $0.01 per share
dei Trading Symbol
TradingSymbol
OCGN
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2020Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
135006644 shares
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14968161 USD
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
7444052 USD
CY2020Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
924500 USD
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
1322167 USD
CY2020Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
7000000 USD
CY2019Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
7000000 USD
CY2020Q2 us-gaap Assets Current
AssetsCurrent
22892661 USD
CY2019Q4 us-gaap Assets Current
AssetsCurrent
15766219 USD
CY2020Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
232354 USD
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
222464 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151157 USD
CY2019Q4 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151016 USD
CY2020Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
482711 USD
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
667747 USD
CY2020Q2 us-gaap Assets
Assets
23758883 USD
CY2019Q4 us-gaap Assets
Assets
16807446 USD
CY2020Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
507864 USD
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
1895613 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2084915 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2270045 USD
CY2020Q2 us-gaap Short Term Borrowings
ShortTermBorrowings
4068176 USD
CY2019Q4 us-gaap Short Term Borrowings
ShortTermBorrowings
0 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175538 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172310 USD
CY2020Q2 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
204860 USD
CY2019Q4 us-gaap Other Liabilities Current
OtherLiabilitiesCurrent
205991 USD
CY2020Q2 us-gaap Liabilities Current
LiabilitiesCurrent
7041353 USD
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
4543959 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75577 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
163198 USD
CY2020Q2 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
2018926 USD
CY2019Q4 us-gaap Long Term Debt Noncurrent
LongTermDebtNoncurrent
1072123 USD
CY2020Q2 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
0 USD
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
9755 USD
CY2020Q2 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
2094503 USD
CY2019Q4 us-gaap Liabilities Noncurrent
LiabilitiesNoncurrent
1245076 USD
CY2020Q2 us-gaap Liabilities
Liabilities
9135856 USD
CY2019Q4 us-gaap Liabilities
Liabilities
5789035 USD
CY2020Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
USD
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2020Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000 shares
CY2020Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
7 shares
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
7 shares
CY2020Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7 shares
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
7 shares
CY2020Q2 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0 USD
CY2020Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.01
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000 shares
CY2020Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
135128144 shares
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
52746728 shares
CY2020Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
135006644 shares
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
52625228 shares
CY2020Q2 us-gaap Common Stock Value
CommonStockValue
1351281 USD
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
527467 USD
CY2020Q2 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
121500 shares
CY2019Q4 us-gaap Treasury Stock Common Shares
TreasuryStockCommonShares
121500 shares
CY2020Q2 us-gaap Treasury Stock Value
TreasuryStockValue
47864 USD
CY2019Q4 us-gaap Treasury Stock Value
TreasuryStockValue
47864 USD
CY2020Q2 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
72357228 USD
CY2019Q4 us-gaap Additional Paid In Capital
AdditionalPaidInCapital
62018632 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59037618 USD
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-51479824 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
14623027 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11018411 USD
CY2020Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
23758883 USD
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
16807446 USD
CY2020Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
42620 USD
CY2019Q2 us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0 USD
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
42620 USD
us-gaap Revenue From Collaborative Arrangement Excluding Revenue From Contract With Customer
RevenueFromCollaborativeArrangementExcludingRevenueFromContractWithCustomer
0 USD
CY2020Q2 us-gaap Revenues
Revenues
42620 USD
CY2019Q2 us-gaap Revenues
Revenues
0 USD
us-gaap Revenues
Revenues
42620 USD
us-gaap Revenues
Revenues
0 USD
CY2020Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1629869 USD
CY2019Q2 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
1240047 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
3282187 USD
us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
5033069 USD
CY2020Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1779016 USD
CY2019Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
1088477 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4055800 USD
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
2136497 USD
CY2020Q2 us-gaap Operating Expenses
OperatingExpenses
3408885 USD
CY2019Q2 us-gaap Operating Expenses
OperatingExpenses
2328524 USD
us-gaap Operating Expenses
OperatingExpenses
7337987 USD
us-gaap Operating Expenses
OperatingExpenses
7169566 USD
CY2020Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-3366265 USD
CY2019Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-2328524 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7295367 USD
us-gaap Operating Income Loss
OperatingIncomeLoss
-7169566 USD
CY2020Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
CY2019Q2 us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-608149 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-1384422 USD
CY2020Q2 ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
0 USD
CY2019Q2 ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
-341136 USD
ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
0 USD
ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
-341136 USD
CY2020Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
433 USD
CY2019Q2 us-gaap Investment Income Interest
InvestmentIncomeInterest
377 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
552 USD
us-gaap Investment Income Interest
InvestmentIncomeInterest
971 USD
CY2020Q2 us-gaap Interest Expense
InterestExpense
248143 USD
CY2019Q2 us-gaap Interest Expense
InterestExpense
261562 USD
us-gaap Interest Expense
InterestExpense
262892 USD
us-gaap Interest Expense
InterestExpense
957031 USD
CY2020Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
0 USD
CY2019Q2 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
184 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-87 USD
us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-232 USD
CY2020Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-247710 USD
CY2019Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-1210286 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-262427 USD
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
-2681850 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3613975 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3538810 USD
us-gaap Net Income Loss
NetIncomeLoss
-7557794 USD
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.80
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3613975 USD
us-gaap Net Income Loss
NetIncomeLoss
-9851416 USD
CY2020Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12546340 USD
CY2019Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12546340 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16160315 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3538810 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20104134 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9851416 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83537463 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6067401 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68082346 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5461576 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3538810 USD
us-gaap Net Income Loss
NetIncomeLoss
-7557794 USD
us-gaap Net Income Loss
NetIncomeLoss
-9851416 USD
CY2020Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-169 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
0 USD
us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-451 USD
CY2020Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3613975 USD
CY2019Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-3538979 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-7557794 USD
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-9851867 USD
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
11018411 USD
CY2020Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
222513 USD
CY2020Q1 us-gaap Net Income Loss
NetIncomeLoss
-3943819 USD
CY2020Q1 us-gaap Stockholders Equity
StockholdersEquity
7297105 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
149209 USD
CY2020Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
-4977876 USD
CY2020Q2 us-gaap Adjustments To Additional Paid In Capital Stock Issued Issuance Costs
AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts
700000 USD
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3613975 USD
CY2020Q2 us-gaap Stockholders Equity
StockholdersEquity
14623027 USD
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-12709539 USD
CY2019Q1 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
415202 USD
CY2019Q1 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-282 USD
CY2019Q1 us-gaap Net Income Loss
NetIncomeLoss
-6312606 USD
CY2019Q1 us-gaap Stockholders Equity
StockholdersEquity
-18607225 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
111807 USD
CY2019Q2 us-gaap Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax
OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax
-169 USD
CY2019Q2 us-gaap Stock Issued During Period Value Conversion Of Convertible Securities
StockIssuedDuringPeriodValueConversionOfConvertibleSecurities
13979789 USD
CY2019Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
1948885 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3538810 USD
CY2019Q2 us-gaap Stockholders Equity
StockholdersEquity
-6105723 USD
us-gaap Profit Loss
ProfitLoss
-7557794 USD
us-gaap Profit Loss
ProfitLoss
-9851416 USD
us-gaap Depreciation
Depreciation
37760 USD
us-gaap Depreciation
Depreciation
19259 USD
ocgn Non Cash Interest Expense
NonCashInterestExpense
262892 USD
ocgn Non Cash Interest Expense
NonCashInterestExpense
937772 USD
ocgn Noncash Lease Expense
NoncashLeaseExpense
95392 USD
ocgn Noncash Lease Expense
NoncashLeaseExpense
154969 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
0 USD
us-gaap Liabilities Fair Value Adjustment
LiabilitiesFairValueAdjustment
-1384422 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371722 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
527009 USD
ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
0 USD
ocgn Gains Losses On Conversion Of Debt
GainsLossesOnConversionOfDebt
-341136 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
165609 USD
us-gaap Other Noncash Income Expense
OtherNoncashIncomeExpense
0 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-498836 USD
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
32986 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
0 USD
us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
25000 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
-1219887 USD
us-gaap Increase Decrease In Accounts Payable And Accrued Liabilities
IncreaseDecreaseInAccountsPayableAndAccruedLiabilities
653767 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-6030925 USD
ocgn Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-95918 USD
ocgn Increase Decrease In Lease Obligations
IncreaseDecreaseInLeaseObligations
-139857 USD
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-7772606 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
34458 USD
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
2067 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
0 USD
us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
130000 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-34458 USD
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-132067 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
11928 USD
us-gaap Finance Lease Principal Payments
FinanceLeasePrincipalPayments
1021 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
16160239 USD
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
1000000 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
592952 USD
us-gaap Payments Of Stock Issuance Costs
PaymentsOfStockIssuanceCosts
0 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
921415 USD
us-gaap Proceeds From Long Term Lines Of Credit
ProceedsFromLongTermLinesOfCredit
4300000 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
5740 USD
us-gaap Payments Of Financing Costs
PaymentsOfFinancingCosts
85233 USD
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
1139720 USD
us-gaap Repayments Of Other Debt
RepaymentsOfOtherDebt
0 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
15331314 USD
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
5213746 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
0 USD
us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
-99 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
7524250 USD
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-949345 USD
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
7595068 USD
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
1778613 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15119318 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
829268 USD
us-gaap Notes Issued1
NotesIssued1
5625000 USD
us-gaap Notes Issued1
NotesIssued1
0 USD
us-gaap Stock Issued1
StockIssued1
331218 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
13979788 USD
CY2019Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
678492 USD
us-gaap Stock Issued1
StockIssued1
0 USD
us-gaap Debt Conversion Original Debt Amount1
DebtConversionOriginalDebtAmount1
0 USD
ocgn Noncash Or Part Noncash Amount Of Deferred Transaction Cost
NoncashOrPartNoncashAmountOfDeferredTransactionCost
0 USD
ocgn Noncash Or Part Noncash Amount Of Deferred Transaction Cost
NoncashOrPartNoncashAmountOfDeferredTransactionCost
1937100 USD
ocgn Noncash Or Part Noncash Operating Lease Right Of Use Asset
NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
0 USD
ocgn Noncash Or Part Noncash Operating Lease Right Of Use Asset
NoncashOrPartNoncashOperatingLeaseRightOfUseAsset
470356 USD
ocgn Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction
DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction
130074 USD
ocgn Deferred Equity Issuance Cost Incurred During Noncash Or Partial Noncash Transaction
DeferredEquityIssuanceCostIncurredDuringNoncashOrPartialNoncashTransaction
152157 USD
us-gaap Nature Of Operations
NatureOfOperations
Nature of Business<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen, Inc. (formerly known as Histogenics Corporation), together with its wholly owned subsidiaries (“Ocugen” or the “Company”), is a biopharmaceutical company focused on discovering, developing and commercializing transformative therapies to cure blindness diseases. The Company is located in Malvern, Pennsylvania, and manages its business as one operating segment.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is developing a modifier gene therapy platform to generate therapies designed to fulfill unmet medical needs in the area of retinal diseases, including inherited retinal diseases ("IRDs") and dry age-related macular degeneration ("AMD"). Ocugen's modifier gene therapy platform is based on nuclear hormone receptors ("NHRs") which have the potential to restore homeostasis, the basic biological processes in the retina. Unlike single-gene replacement therapies, which only target one genetic mutation, Ocugen believes that its gene therapy platform, through its use of NHRs, represents a novel approach in that it may address multiple retinal diseases with one product. </span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen's first gene therapy candidate, OCU400, is being developed to treat retinitis pigmentosa ("RP"), a group of rare genetic disorders that involves a breakdown and loss of cells in the retina and can lead to visual impairment and blindness. Ocugen has received four Orphan Drug Designations ("ODDs") from the Food and Drug Administration ("FDA") for the treatment of certain disease genotypes: nuclear receptor subfamily 2 group E member 3 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">NR2E3</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">"), centrosomal protein 290 ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">CEP290</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">"), rhodopsin ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RHO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">"), and phosphodiesterase 6B ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">PDE6B</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") mutation-associated RP. The third ODD, for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RHO</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation, was received in late July 2020. The fourth ODD, for the </span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">PDE6B</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;"> mutation, was received in early August 2020. Ocugen is planning to initiate two Phase 1/2a clinical trials for OCU400 in the second half of 2021. Ocugen's second gene therapy candidate, OCU410, is being developed to utilize the nuclear receptor genes RAR-related orphan receptor A ("</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%;">RORA</span><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">") for the treatment of dry AMD. This candidate is currently in preclinical development.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen is also conducting preclinical development for a novel biologic product candidate, OCU200. OCU200 is a novel fusion protein designed to treat diabetic macular edema ("DME"), diabetic retinopathy ("DR") and wet AMD. Ocugen expects to initiate a Phase 1/2a clinical trial for OCU200 in the first half of 2022 and plans to expand the therapeutic applications of OCU200 beyond DME, DR and wet AMD to potentially include macular edema following retinal vein occlusion and myopic choroidal neovascularization.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">Ocugen was developing OCU300, a small molecule therapeutic for the treatment of symptoms associated with ocular graft versus-host disease. On June 1, 2020, Ocugen announced that it had discontinued the Phase 3 trial of OCU300 based on results of a pre-planned interim sample size analysis conducted by an independent Data Monitoring Committee, which indicated the trial was unlikely to meet its co-primary endpoints upon completion. The trial was not stopped based on safety concerns. Ocugen is no longer pursuing the development of this product candidate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Merger with Histogenics</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">On September 27, 2019, the Company completed its reverse merger with Ocugen OpCo, Inc. (“OpCo”) in accordance with the terms of the Agreement and Plan of Merger and Reorganization, dated as of April 5, 2019, by and among Histogenics Corporation ("Histogenics"), OpCo and Restore Merger Sub, Inc., a wholly owned subsidiary of Histogenics (“Merger Sub”), as amended (the “Merger Agreement”), pursuant to which Merger Sub merged with and into OpCo, with OpCo surviving as a wholly owned subsidiary of Histogenics (the “Merger”). Immediately after completion of the Merger, Histogenics changed its name to Ocugen, Inc. and the business conducted by Ocugen, Inc. became the business conducted by OpCo. OpCo is deemed to be the accounting acquirer. Accordingly, the historical financial statements of OpCo became the Company’s historical financial statements, including the comparative prior periods. See Note 3 for additional information.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Reverse Stock Split</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In connection with, and immediately prior to the completion of the Merger, Histogenics effected a reverse stock split of the common stock, at a ratio of 1-for-60 (the ‘‘Reverse Stock Split’’). Under the terms of the Merger Agreement, the Company issued common stock to OpCo’s stockholders at an exchange rate of 0.4794 shares of common stock, after taking into account the Reverse Stock Split, for each share of OpCo’s common stock outstanding immediately prior to the Merger.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The capital structure, including the number of shares of common stock issued appearing in the condensed consolidated balance sheets for the periods presented, reflects that of Ocugen. All references in the condensed consolidated financial statements to the number of shares and per-share amounts of common stock have been retroactively restated to reflect the exchange rate.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Going Concern</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has incurred recurring losses and negative cash flows from operations since inception and has funded its operating losses through the sale of common stock, warrants to purchase common stock, the issuance of convertible notes, debt, and grant proceeds. The Company incurred net losses of approximately $7.6 million and $9.9 million for the six months ended June 30, 2020 and 2019, respectively. As of June 30, 2020, the Company had an accumulated deficit of $59.0 million and cash, cash equivalents and restricted cash totaling $15.1 million.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The Company has a limited operating history and its prospects are subject to risks, expenses and uncertainties frequently encountered by companies in its industry. The Company intends to continue its research and development efforts for its product candidates, which will require significant funding. If the Company is unable to obtain additional financing in the future or research and development efforts require higher than anticipated capital, there may be a negative impact on the financial viability of the Company. The Company plans to increase working capital by raising additional capital through public and private placements of equity and/or debt, payments from potential strategic research and development arrangements, sale of assets, and licensing and/or collaboration arrangements with pharmaceutical companies or other institutions. Such financing may not be available at all, or on terms that are favorable to the Company. While management of the Company believes that it has a plan to fund ongoing operations, its plan may not be successfully implemented. Failure to generate sufficient cash flows from operations, raise additional capital through one or more financings, or appropriately manage certain discretionary spending could have a material adverse effect on the Company’s ability to achieve its intended business objectives.</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">As a result of these factors, together with the anticipated increase in spending that will be necessary to continue to develop the Company’s product candidates, there is substantial doubt about the Company’s ability to continue as a going concern within one year after the date that these condensed consolidated financial statements are issued. The condensed consolidated financial statements do not contain any adjustments that might result from the resolution of any of the above uncertainties.</span></div>
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1 segment
ocgn Number Of Orphan Drug Designations
NumberOfOrphanDrugDesignations
4 orphan_drug_designation
us-gaap Net Income Loss
NetIncomeLoss
-7600000 USD
us-gaap Net Income Loss
NetIncomeLoss
-9900000 USD
CY2020Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-59000000.0 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15100000 USD
us-gaap Basis Of Accounting
BasisOfAccounting
<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Basis of Presentation and Consolidation</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">The accompanying condensed consolidated financial statements included herein have been prepared in conformity with accounting principles generally accepted in the United States (“GAAP”) and under the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim reporting. The accompanying unaudited condensed consolidated financial statements include all adjustments, consisting of normal recurring adjustments, that are necessary to present fairly the Company’s financial position, results of operations, and cash flows. The condensed consolidated results of operations are not necessarily indicative of the results that may occur for the full fiscal year. Certain information and footnote disclosures of the Company normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted under the SEC’s rules and regulations. These condensed consolidated financial statements should be read in conjunction with the audited financial statements and accompanying notes thereto for the year ended December 31, 2019, included in the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 (the "2019 Annual Report").</span></div>
us-gaap Use Of Estimates
UseOfEstimates
<div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%;">Use of Estimates</span></div><div style="margin-top:12pt;"><span style="background-color:rgb(255,255,255, 0.0);color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;">In preparing the condensed consolidated financial statements in conformity with GAAP, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements, as well as the reported amounts of expenses during the reporting period. Due to inherent uncertainty involved in making estimates, actual results reported in future periods may be affected by changes in these estimates. On an ongoing basis, the Company evaluates its estimates and assumptions. These estimates and assumptions primarily include those used in the accounting for clinical trial accruals, warrant transactions, asset held for sale, and the valuation of debt and equity instruments, including embedded derivatives and stock-based compensation.</span></div>
CY2019Q4 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
7000000.0 USD
CY2020Q2 us-gaap Assets Held For Sale Not Part Of Disposal Group Current
AssetsHeldForSaleNotPartOfDisposalGroupCurrent
7000000.0 USD
CY2020Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
14968161 USD
CY2020Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
151157 USD
CY2019Q2 us-gaap Restricted Cash Noncurrent
RestrictedCashNoncurrent
150776 USD
CY2020Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
15119318 USD
CY2019Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
829268 USD
us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Expiration Period
SharebasedCompensationArrangementBySharebasedPaymentAwardExpirationPeriod
P10Y
CY2019Q4 ocgn Number Of Series Of Warrants Issued
NumberOfSeriesOfWarrantsIssued
3 series
CY2020Q2 us-gaap Net Income Loss
NetIncomeLoss
-3613975 USD
CY2019Q2 us-gaap Net Income Loss
NetIncomeLoss
-3538810 USD
us-gaap Net Income Loss
NetIncomeLoss
-7557794 USD
us-gaap Net Income Loss
NetIncomeLoss
-9851416 USD
CY2020Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12546340 USD
CY2019Q2 us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
12546340 USD
us-gaap Preferred Stock Dividends And Other Adjustments
PreferredStockDividendsAndOtherAdjustments
0 USD
CY2020Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-16160315 USD
CY2019Q2 us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-3538810 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-20104134 USD
us-gaap Net Income Loss Available To Common Stockholders Basic
NetIncomeLossAvailableToCommonStockholdersBasic
-9851416 USD
CY2020Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
83537463 shares
CY2019Q2 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
6067401 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
68082346 shares
us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
5461576 shares
CY2020Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.19
CY2019Q2 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.58
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-0.30
us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-1.80
CY2020Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5373981 shares
CY2019Q2 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1372883 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5373981 shares
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1372883 shares
CY2020Q2 ocgn Research And Development Expenses Current
ResearchAndDevelopmentExpensesCurrent
60458 USD
CY2019Q4 ocgn Research And Development Expenses Current
ResearchAndDevelopmentExpensesCurrent
271322 USD
CY2020Q2 ocgn Accrued Liabilities Clinical
AccruedLiabilitiesClinical
435281 USD
CY2019Q4 ocgn Accrued Liabilities Clinical
AccruedLiabilitiesClinical
421788 USD
CY2020Q2 ocgn Accrued Liabilities Professional Fees
AccruedLiabilitiesProfessionalFees
376031 USD
CY2019Q4 ocgn Accrued Liabilities Professional Fees
AccruedLiabilitiesProfessionalFees
917568 USD
CY2020Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
508474 USD
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
624420 USD
CY2020Q2 ocgn Accrued Severance Related Liabilities Current
AccruedSeveranceRelatedLiabilitiesCurrent
693585 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Two
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo
0 USD
CY2020Q2 us-gaap Long Term Debt
LongTermDebt
6087102 USD
CY2019Q4 us-gaap Long Term Debt
LongTermDebt
1072123 USD
CY2019Q2 ocgn Common Stock Shares Agreed To Be Sold Stock Subscription Agreement
CommonStockSharesAgreedToBeSoldStockSubscriptionAgreement
100000 shares
CY2019Q2 us-gaap Sale Of Stock Price Per Share
SaleOfStockPricePerShare
12.41
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
900000 USD
CY2019Q2 us-gaap Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature
AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature
13000000.0 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Three
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree
0 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year
LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear
4485280 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Next Twelve Months
LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths
421415 USD
CY2019Q4 ocgn Accrued Severance Related Liabilities Current
AccruedSeveranceRelatedLiabilitiesCurrent
0 USD
CY2020Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
11086 USD
CY2019Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
34947 USD
CY2020Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2084915 USD
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
2270045 USD
CY2020Q2 us-gaap Long Term Debt Maturities Repayments Of Principal In Year Four
LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour
0 USD
CY2020Q2 ocgn Long Term Debt Maturity After Year Four
LongTermDebtMaturityAfterYearFour
1500000 USD
CY2020Q2 us-gaap Debt Instrument Carrying Amount
DebtInstrumentCarryingAmount
6406695 USD
CY2020Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
149209 USD
CY2019Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
111807 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
371722 USD
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
527009 USD
CY2020Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions
1600000 USD
CY2020Q2 ocgn Number Of Equity Compensation Plans
NumberOfEquityCompensationPlans
2 segment
CY2019Q4 ocgn Share Based Compensation Arrangement By Share Based Payment Award Automatic Increase In Shares To Be Issue Percentage
ShareBasedCompensationArrangementByShareBasedPaymentAwardAutomaticIncreaseInSharesToBeIssuePercentage
0.04
CY2020Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.28
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue
0.34
CY2020Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
47696 USD
CY2019Q2 us-gaap Operating Lease Cost
OperatingLeaseCost
81696 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
95392 USD
us-gaap Operating Lease Cost
OperatingLeaseCost
154969 USD
CY2020Q2 us-gaap Variable Lease Cost
VariableLeaseCost
20077 USD
CY2019Q2 us-gaap Variable Lease Cost
VariableLeaseCost
21031 USD
us-gaap Variable Lease Cost
VariableLeaseCost
41246 USD
us-gaap Variable Lease Cost
VariableLeaseCost
36879 USD
CY2020Q2 us-gaap Lease Cost
LeaseCost
67773 USD
CY2019Q2 us-gaap Lease Cost
LeaseCost
102727 USD
us-gaap Lease Cost
LeaseCost
136638 USD
us-gaap Lease Cost
LeaseCost
191848 USD
CY2020Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
260708 USD
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
344574 USD
CY2020Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
175538 USD
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
172310 USD
CY2020Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
75577 USD
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
163198 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
251115 USD
CY2019Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
335508 USD
CY2020Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P1Y6M
CY2019Q2 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P2Y6M
CY2020Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2019Q2 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.076
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
96112 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
160909 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
11354 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
268375 USD
CY2020Q2 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
17260 USD
CY2020Q2 us-gaap Operating Lease Liability
OperatingLeaseLiability
251115 USD
CY2020Q2 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P5Y
CY2020Q2 us-gaap Lessee Finance Lease Discount Rate
LesseeFinanceLeaseDiscountRate
0.076
CY2020Q2 us-gaap Finance Lease Liability Payments Remainder Of Fiscal Year
FinanceLeaseLiabilityPaymentsRemainderOfFiscalYear
11928 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due Next Twelve Months
FinanceLeaseLiabilityPaymentsDueNextTwelveMonths
9941 USD
CY2020Q2 us-gaap Finance Lease Liability Payments Due
FinanceLeaseLiabilityPaymentsDue
21869 USD
CY2020Q2 us-gaap Finance Lease Liability Undiscounted Excess Amount
FinanceLeaseLiabilityUndiscountedExcessAmount
809 USD
CY2020Q2 us-gaap Finance Lease Liability
FinanceLeaseLiability
21060 USD
ocgn Number Of Orphan Drug Designations
NumberOfOrphanDrugDesignations
4 orphan_drug_designation

Files In Submission

Name View Source Status
0001628280-20-012662-index-headers.html Edgar Link pending
0001628280-20-012662-index.html Edgar Link pending
0001628280-20-012662.txt Edgar Link pending
0001628280-20-012662-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
ocgn-20200630.htm Edgar Link pending
ocgn-20200630.xsd Edgar Link pending
ocgn-20200630x10qxex311.htm Edgar Link pending
ocgn-20200630x10qxex312.htm Edgar Link pending
ocgn-20200630x10qxex321.htm Edgar Link pending
ocgn-20200630_cal.xml Edgar Link unprocessable
ocgn-20200630_def.xml Edgar Link unprocessable
ocgn-20200630_htm.xml Edgar Link completed
ocgn-20200630_lab.xml Edgar Link unprocessable
ocgn-20200630_pre.xml Edgar Link unprocessable
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R56.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending